JACC: HEART FAILURE VOL. 6, NO. 8, 2018

PUBLISHED BY ELSEVIER

SPECIAL ISSUE: HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF)

***JACC: HEART FAILURE* EXPERT SCIENTIFIC PANEL**

Heart Failure With Preserved Ejection Fraction Expert Panel Report

Current Controversies and Implications for Clinical Trials

Kishan S. Parikh, MD,[a,b] Kavita Sharma, MD,[c] Mona Fiuzat, PharmD,[a,b] Howard K. Surks, MD,[d] Jyothis T. George, MD,[e] Narimon Honarpour, MD, PhD,[f] Christopher Depre, MD, PhD,[f] Patrice Desvigne-Nickens, MD,[g] Richard Nkulikiyinka, MD,[h] Gregory D. Lewis, MD,[i] Mardi Gomberg-Maitland, MD, MSc,[j] Christopher M. O'Connor, MD,[j] Norman Stockbridge, MD,[k] Robert M. Califf, MD,[b,l,m] Marvin A. Konstam, MD,[n] James L. Januzzi, Jr, MD,[o] Scott D. Solomon, MD,[p] Barry A. Borlaug, MD,[q] Sanjiv J. Shah, MD,[r] Margaret M. Redfield, MD,[q] G. Michael Felker, MD[a,b]

***JACC: HEART FAILURE* CME/MOC**

This article has been selected as the month's *JACC: Heart Failure* CME/MOC activity, available online at http://www.acc.org/jacc-journals-cme by selecting the *JACC* Journals CME/MOC tab.

Accreditation and Designation Statement

The American College of Cardiology Foundation (ACCF) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The ACCF designates this Journal-based CME/MOC activity for a maximum of 1 *AMA PRA Category 1 Credit(s)*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Method of Participation and Receipt of CME/MOC Certificate

To obtain credit for *JACC: Heart Failure* CME/MOC, you must:

1. Be an ACC member or *JACC* subscriber.
2. Carefully read the CME/MOC-designated article available online and in this issue of the journal.
3. Answer the post-test questions. At least 2 out of the 3 questions provided must be answered correctly to obtain CME/MOC credit.
4. Complete a brief evaluation.
5. Claim your CME/MOC credit and receive your certificate electronically by following the instructions given at the conclusion of the activity.

CME/MOC Objectives for This Article: Upon completion of this activity, the learner should be able to: 1) identify key knowledge gaps relevant to clinicians, investigators, industry, and regulators in the current HFpEF field; 2) discuss results of prior HFpEF trials and potential pitfalls of trial design; and 3) select appropriate strategies to diagnose HFpEF and identify subpopulations that may fit a targeted therapy.

CME/MOC Editor Disclosure: Editor-in-Chief Christopher M. O'Connor, MD, has received consultant fees/honoraria from AbbVie, Inc., Actelion Pharmaceuticals Ltd., Bayer, Bristol Myers Squibb, Cardiorentis, Merco & Co., Inc., ResMed, and Roche Diagnostics; and ownership interest in Biscardia, LLC. Executive Editor Mona Fiuzat, PharmD, has received research support from ResMed, Gilead, Critical Diagnostics, Otsuka, and Roche Diagnostics. Tariq Ahmad, MD, MPH, has received a travel scholarship from Thoratec. Abhinav Sharma, MD, has received support from Bayer-Canadian Cardiovascular Society, Alberta Innovates Health Solution, Roche Diagnostics, and Takeda. Mitchell Psotka, MD, PhD, and Kishan Parikh, MD, have no relationships relevant to the contents of this paper to disclose.

Author Disclosures: Dr. Fiuzat has received personal fees from ResMed outside the submitted work. Dr. Surks is an employee of Sanofi. Dr. George is an employee of Boehringer Ingelheim. Dr. Honarpour is an employee of Amgen and has received stock grants from Amgen, Inc. Dr. Depre is an employee of Amgen, Inc. Dr. Nkulikiyinka is an employee and shareholder of Bayer AG. Dr. Lewis has received grants from Abbott Vascular, Ironwood, National Institutes of Health, and American Heart Association; and is a consultant for Amgen, Luitpold, and Cytokinetics. Dr. Gomberg-Maitland has received grants and other support from Actelion; personal fees from Bayer, Acceleron, Medronic, Arena, Merck, St. Jude's/Abbott,

From the [a]Duke Clinical Research Institute, Durham, North Carolina; [b]Duke University School of Medicine, Durham, North Carolina; [c]Johns Hopkins University, Baltimore, Maryland; [d]Sanofi, Bridgewater, New Jersey; [e]Boehringer Ingelheim Clinical Development, Ingelheim, Germany; [f]Amgen, Inc., Thousand Oaks, California; [g]National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, Maryland; [h]Bayer AG, Wuppertal, Germany; [i]Massachusetts General Hospital, Boston, Massachusetts; [j]Inova Heart and Vascular Institute, Falls Church, Virginia; [k]U.S. Food and Drug Administration, Silver Spring, Maryland; [l]Stanford University, Stanford, California; [m]Verily Life Sciences, San Francisco, California; [n]Tufts Medical Center, Boston, Massachusetts; [o]Brigham and Women's Hospital, Boston, Massachusetts; [p]Harvard Medical School, Wellesley, Massachusetts; [q]Mayo Clinic, Rochester,

ISSN 2213-1779/$36.00 https://doi.org/10.1016/j.jchf.2018.06.008

and Liquidia; other support from Reata and PCORI; grants, personal fees, and other support from United Therapeutics; grants from AADi; and personal fees from Janssen during the conduct of the study. Dr. O'Connor has received personal fees from ResMed, Bayer, Stealth Peptides, Bristol-Myers Squibb Foundation, Dey, L.P., and Merck outside the submitted work. Dr. Califf served as Commissioner for Food and Drugs at the U.S. Food and Drug Administration from 2016 to 2017 and as Deputy Commissioner for Medical Products and Tobacco from 2015 to 2016; is employed as a scientific advisor by Verily Life Sciences (Alphabet); has received stock from Verily Life Sciences; is a consultant for Merck, Amgen, and Boehringer Ingelheim; and receives consulting payments from Merck. Dr. Konstam has received other support from Amgen, Bristol-Myers Squibb, Boehringer Ingelheim, and Novartis; and grants and other support from Ironwood and Livanova outside the submitted work. Dr. Januzzi has received grants from Roche Diagnostics, Abbott, Singulex, Prevencio, and Novartis; grants and personal fees from Janssen; and personal fees from Critical Diagnostics outside the submitted work. Dr. Solomon has received grants and personal fees from Novartis, AstraZeneca, Bayer, Bristol-Myers Squibb, Alnylam, GlaxoSmithKline, Myokardia, and Amgen; grants from Ionis; and personal fees from Corvia, Roche, and Merck outside the submitted work. Dr. Shah has received receiving research funding from the National Institutes of Health (R01 HL107577, R01 HL127028), the American Heart Association (#16SFRN28780016 and #15CVGPSD27260148), Actelion, AstraZeneca, Corvia, and Novartis; and consulting fees from Actelion, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiora, Eisai, Ironwood, Merck, Novartis, Sanofi, Tenax, and United Therapeutics. Dr. Felker has received grant funding from the National Heart, Lung, and Blood Institute, American Heart Association, Novartis, Amgen, Cytokinetics, Merck, and Roche Diagnostics; and consulting for Novartis, Amgen, Roche Diagnostics, Medtronic, Bristol-Myers Squibb, GlaxoSmithKline, Cardionomic, Cytokinetics, Myokardia, Stealth, Innolife, and EBR Systems. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Medium of Participation: Print (article only); online (article and quiz).

CME/MOC Term of Approval

Issue date: August 2018
Expiration date: July 31, 2019

Minnesota; and [†]Northwestern University, Chicago, Illinois. Dr. Fiuzat has received personal fees from ResMed outside the submitted work. Dr. Surks is an employee of Sanofi. Dr. George is an employee of Boehringer Ingelheim. Dr. Honarpour is an employee of Amgen and has received stock grants from Amgen, Inc. Dr. Depre is an employee of Amgen, Inc. Dr. Nkulikiyinka is an employee and shareholder of Bayer AG. Dr. Lewis has received grants from Abbott Vascular, Ironwood, National Institutes of Health, and American Heart Association; and is a consultant for Amgen, Luitpold, and Cytokinetics. Dr. Gomberg-Maitland has received grants and other support from Actelion; personal fees from Bayer, Acceleron, Medronic, Arena, Merck, St. Jude's/Abbott, and Liquidia; other support from Reata and PCORI; grants, personal fees, and other support from United Therapeutics; grants from AADi; and personal fees from Janssen during the conduct of the study. Dr. O'Connor has received personal fees from ResMed, Bayer, Stealth Peptides, Bristol-Myers Squibb Foundation, Dey, L.P., and Merck outside the submitted work. Dr. Califf served as Commissioner for Food and Drugs at the U.S. Food and Drug Administration from 2016 to 2017 and as Deputy Commissioner for Medical Products and Tobacco from 2015 to 2016; is employed as a scientific advisor by Verily Life Sciences (Alphabet); has received stock from Verily Life Sciences; is a consultant for Merck, Amgen, and Boehringer Ingelheim; and receives consulting payments from Merck. Dr. Konstam has received other support from Amgen, Bristol-Myers Squibb, Boehringer Ingelheim, and Novartis; and grants and other support from Ironwood and Livanova outside the submitted work. Dr. Januzzi has received grants from Roche Diagnostics, Abbott, Singulex, Prevencio, and Novartis; grants and personal fees from Janssen; and personal fees from Critical Diagnostics outside the submitted work. Dr. Solomon has received grants and personal fees from Novartis, AstraZeneca, Bayer, Bristol-Myers Squibb, Alnylam, GlaxoSmithKline, Myokardia, and Amgen; grants from Ionis; and personal fees from Corvia, Roche, and Merck outside the submitted work. Dr. Shah has received receiving research funding from the National Institutes of Health (R01 HL107577, R01 HL127028), the American Heart Association (#16SFRN28780016 and #15CVGPSD27260148), Actelion, AstraZeneca, Corvia, and Novartis; and consulting fees from Actelion, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiora, Eisai, Ironwood, Merck, Novartis, Sanofi, Tenax, and United Therapeutics. Dr. Felker has received grant funding from National Heart, Lung, and Blood Institute, American Heart Association, Novartis, Amgen, Cytokinetics, Merck, and Roche Diagnostics; and consulting for Novartis, Amgen, Roche Diagnostics, Medtronic, Bristol-Myers Squibb, GlaxoSmithKline, Cardionomic, Cytokinetics, Myokardia, Stealth, Innolife, and EBR Systems. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Barry H. Greenberg, MD, served as Guest Editor for this paper.

Manuscript received April 6, 2018; revised manuscript received June 20, 2018, accepted June 20, 2018.